BACKGROUND: Many studies have showed that apoptosis of endothelial cells plays a curial role in the progress of sepsis. But the role of simvastatin in apoptosis of endothelial cells induced by sepsis is not clear. The present study aimed to investigate the role of simvastatin in apoptosis of endothelial cells induced by sepsis and its mechanism.
INTRODUCTION
Sepsis is an excessive body inflammation reaction caused by infection, and its specifi c pathogenesis is very complex. [1] One of the important hallmarks of sepsis is microvascular dysfunction, in which the activation and dysfunction of endothelial cells seem to play a pivotal role. In infection and subsequent sepsis, components of the bacterial cell wall, such as lipopolysaccharide (LPS), activate pattern recognition receptors on the endothelial surface. [2, 3] Once an inflammatory response has been instigated, a large number of host-derived mediators, including cytokines, chemokines, and products of the complement system, are also able to activate endothelial cells. The endothelium responds to these mediators with structural changes such as cytoplasmic swelling and detachment and importantly, also with functional changes such as the expression of adhesion molecules, resulting in increased platelet adhesion and leukocyte traffi cking. An important feature of endothelial dysfunction in sepsis is increased vascular permeability, resulting in World J Emerg Med, Vol 5, No 4, 2014 Fu et al redistribution of body fluid and edema. Fluid leakage from the intravascular space contributes to hypovolemia and hypotension, which are the important signs of sepsis syndrome. [4] Normally, only a small portion of endothelial cells is apoptotic (<0.1%). LPS has been shown to induce endothelial apoptosis in vitro and also in vivo, although not in all studies. [5] Interaction with other cells may infl uence endothelial apoptosis; for example, LPS-activated monocytes have been shown to contribute to endothelial apoptosis in vitro. [6] Endothelial apoptosis has been shown to contribute to a procoagulant state in vitro. [7] It plays a central role in the pathogenesis of some diseases, and the prevention of endothelial apoptosis can cause significant improvements in the patient's outcome. [8] Recent studies [9, 10] have shown that simvastatin has immunomodulatory and anti-infl ammatory effects, which were not dependent on the lipid-lowering effect. An animal study [11] showed that simvastatin is an effective agent that reduces cytokines levels and leukocyte count in sepsis, and is well-known for the lipid-lowering effects. Simvastatin has important anti-inflammatory effects on abdominal sepsis in rats. Another study [12] demonstrated that high-dose simvastatin (80 mg) may be useful for patients with acute systemic infl ammation and associated vascular hyporeactivity during endotoxemia. Simvastatin reduces recruitment and activation of neutrophils, hereby protecting from LPS-induced acute lung injury (ALI).
So far, though a great deal of studies have shown that simvastatin has an obvious anti-inflammatory effect on sepsis, but its specific mechanism for the treatment of sepsis is not clear. Apoptosis of endothelial cells plays an important role in the pathogenesis of sepsis. Few studies have been reported whether simvastatin can reduce apoptosis of endothelial cells induced by sepsis. The present study aimed to investigate the role of simvastatin in apoptosis of endothelial cells induced by sepsis as well as its mechanism.
METHODS

Animals and experimental groups
Fifty adult male Sprague-Dawley (SD) rats weighing 250-300 g (body weight) (Hunan SJA Laboratory Animal Co.Ltd, PR China) were used as the sepsis model of cecal ligation and puncture (CLP) as described previously. [13] The serum was collected at 6 hours following CLP. The serum from the rat sepsis model was prepared for another part of the experiment. Animals handling and experiments were approved by the Institutional Animal Care and Use Committee, University of South China, China.
Human umbilical vein endothelial cells (HUVECs), ECV-304 cells, were randomly divided into three groups: control group, rat sepsis serum intervention group (sepsis group) and simvastatin+sepsis serum intervention group (simvastatin group). The HUVECs in the control group were cultured in DMEN, in the sepsis group in DMEN at the concentration of 20% for sepsis serum, and in the simvstatin group in DMEN at the concentration of 20% for sepsis serum and 1 µmol/L simvastatin. The HUVECs were used in the experiments 24 hours after the onset of culture.
MTT assay
MTT assay was used to measure cell proliferation as described previously. [14] The specific MTT assay was carried out with the kit (Nanjing KeyGEN Biotech CO., LTD, China) according to the manufacturer's protocol. Briefly, cells were seeded in 96-well tissue culture plates at a concentration of 4×10 3 cells/well. When cells reached approximately 70% confl uence, the medium was changed from DMEM-15 to DMEM at the concentration of 20% of rat sepsis serum, the concentration of 20% of rat sepsis serum including 1 µmol/L smvastatin, respectively, and maintained for 24 hours. The serum-starved cells were maintained for 24 hours in each culture condition. At the end of culture, the MTT (50 μg/mL) was added and further maintained for 2 hours at 37 °C. The MTTcontaining medium was discarded, and 100 μL of undiluted dimethyl sulfoxide was added to the cells. After 30-minute incubation at room temperature, absorbance (A value) of the converted dye was measured at a wavelength of 450 nm with background subtraction at 650 nm using a spectrophotometric plate reader (Benchmark Plus Microplate Spectrophotometer; Bio-Rad Laboratories, Hercules, CA). Measurements were repeated three times to get a mean value. Relative growth rate = (intervention group A value / control group A value) × 100%.
Hoechst staining
Apoptosis was determined by incubating the cells with 10 μg/mL Hoechst 33 342 for 30 minutes at 37 °C using the Hoechst staining kit (Nanjing KeyGEN Biotech, CO.,LTD, China) according to the manufacturer's protocol and scoring the percentage of cells having intensely condensed chromatin and/or fragmented nuclei by fl uorescence microscopy. Apoptotic cells showed with strong blue fl uorescence, normal cells did with only weak fluorescence, while dead cells were not stained in the fl uorescence microscopy.
Flow cytometry
Cells were incubated with fl uorescein isothiocyanate (FITC)-conjugated Annexin-V according to the recommendations of the manufacturer (Nanjing KeyGEN Biotech. CO., LTD, China). Nuclei were counterstained with propidium iodide (PI) and screened by flow cytometry (approximately 10 000 events). A cell scattergram which was composed of four quadrants would be given by flow cytometry. And analysis of apoptosis rate (including early apoptotic cells and late apoptotic cells) would refer to Wendelina method. [15] 
RT-PCR analysis
Logarithmic phase cells were collected, and a single cell suspension of 1×10 5 /mL was prepared with culture medium. Of the suspension, 300 μL per well was seeded in a 6-well plate. After 24 hours' adherent growth, the culture medium was drained, and washed with PBS three times. Then, the cells were incubated with conditioned medium for 24 hours. The cells of each group were incubated in three different wells and the experiment repeated 3 times.
Total RNA was extracted from the cells using RNAesy mini kit (TAKARA Biotechnology (Dalian) Co. Ltd, China) according to the manufacturer's protocol. The quantity of total RNA was measured with a UV spectrophotometer (Biochrom Ltd, England). For the reverse transcription, 2 μg of total RNA was combined with 1 μm of Oligo (dT) 15 primer (Invitrogen, CA, USA). The mixture was then heated at 70 °C for 5 minutes and then placed on ice. Single-strand cDNA was synthesized from the RNA by adding the following reagents (final concentrations): 1×first strand buffer, 1 U/μL RNAsin, 25 mL of each dNTP and 200 U M-MLV reverse transcriptase (Promega, WI, USA). The reaction mixture (20 μL) was incubated at 42 °C for 50 minutes and the mixture was heated to 95 °C for 5 minutes in order to terminate the reaction. The samples were stored at -20 °C for PCR analysis.
PCR was carried out on a Life Eco Thermocycler (Bio-Rad Laboratories, Inc, USA) using kit (TAKARA Biotechnology (Dalian) Co. Ltd, China) according to the manufacturer's instructions. Briefly, a total volume of 20 μL mix was prepared with 2 μL cDNA, 10 μL PCR Master mix, 0.5 μL forward primer, 0.5 μL reverse primer, and ddH 2 O 7 μL. The oligonucleotide primer sequences used for Bcl-2, Bax and b-actin are as follows: Bcl-2 (242 bp), forward primer: 5CTCGTCGC TACCGTCGTGACTTCG3; reverse primer: 5CAGATG C C G G T T C A G G TA C T C A G T C 3 ; B a x ( 5 4 2 b p ) , forward primer: 5ATGGAGGGGTCCGGGGAG3, reverse primer: 5TGGAAGAAGATGGGCTGA3; β-actin (852 bp), forward primer: 5CACGATGGAGG G G C C G G A C T C AT C 3 , a n d r e v e r s e p r i m e r 5'TAAAGACCTCTATGCCAACACAGT3.Thermal cycling was carried out. The first segment of the amplification cycle consisted of a pre-denaturation programme at 95 °C for 3 minutes, denaturation programme at 95 °C for 30 seconds. The second segment consisted of denaturation, primer annealing, elongation and a quantifi cation programme repeated for 34 cycles, and ultimately extends to 72 °C for 5 minutes. The products preserved at 4 °C. Amplifications were confirmed by standard submarine gel electrophoresis, using 2% w/v low-melting agarose/TBE gels (NuSieve, FMC BioProducts), stained with ethidium bromide. The relative mRNA levels were determined with β-actin as the internal control.
Statistical analysis
All values were presented as mean±SD. Statistical analyses were conducted with commercially available software SPSS 13.0. Difference of the relative growth rate of HUVECs in each group was determined by the results of independent-samples t test, The difference between the absorbance values and the apoptotic rate of HUVECs was determined by one-way ANOVA. P<0.05 was considered statistically signifi cant.
RESULTS
Relative growth rate of HUVECs in each group detected by MTT assay
The relative growth rate of HUVECs was reduced significantly in the sepsis group compared with the control group. After the intervention with simvastatin, the relative growth rate of HUVECs was increased significantly in the simvastatin group compared with the sepsis group. The rates in the sepsis group and simvastatin group were (64.06±1.70)% and (37.59±2.13)% respectively (t=-16.846, P=0.000) (Figure 1 ). These results showed that simvastatin can alleviate injury of endothelial cells induced by sepsis.
Apoptosis detected by staining with Hoechst 33342
Normal living cells with Hoechst staining showed blue fluorescence uniformly in the control group, while apoptotic cells showed hyperchromatic and dense fl uorescent particles within the massive apoptotic nuclei or cytoplasm in the fl uorescence microscopy in the sepsis group and the simvastatin group. Apoptotic HUVECs reduced signifi cantly in the simvastatin group compared with the sepsis group (P<0.05) (Figure 2 ).
Apoptosis detected by fl ow cytometry
Flow cytometry showed the significant difference Simvastatin Control Sepsis of apoptosis rates of HUVECs between the two groups (F=15.317, P=0.004). The apoptosis rate of HUVECs in the sepsis group increased signifi cantly compared with the control group (P=0.001). Meanwhile, the apoptosis rate of the simvastatin group was signifi cantly reduced compared with that of the sepsis group (P=0.027) (Figure 3 ).
Expression of Bcl-2 and Bax mRNA
PCR analysis showed significant difference of Bcl-2 and Bax mRNA in HUVECs of each group. The expression of Bcl-2 mRNA decreased in the sepsis group compared with the control group, whereas the Bcl-2 expression increased in the simvastatin group compared with the sepsis group (Figure 4 A, C) . The expression of Bax in the sepsis group and the simvastatin group was conversely changed. The expression of Bax mRNA increased significantly in the sepsis group compared with the control group. The epression of Bax mRNA decreased in the simvastatin group compared with the sepsis group (Figure 4 B, D) . 
DISCUSSION
Injury of endothelial cells induced by sepsis play a crucial role in the progress of sepsis and its severity is significantly related to prognosis. Studies [16] [17] [18] [19] [20] [21] have shown that endothelial activation and dysfunction seem to play a pivotal role in sepsis. It has been reported that endothelial apoptosis could be the pivotal event in the pathogenesis of systemic inflammatory response syndrome, sepsis, acute respiratory distress syndrome, and multiple-organ dysfunction syndrome. [19] Endothelial apoptosis plays a central role in the pathogenesis of some diseases, and the prevention of endothelial apoptosis can signifi cantly improve the patient's outcome. [8] At the same time, microparticles are circulating cell fragments derived from activated or apopototic cells. In sepsis, circulating microparticles derived from platelets, monocytes, and endothelial cells have been identifi ed. [17, 22, 23] Although many aspects of microparticle function are still unclear, they are increasingly recognized as important regulators of cell-to-cell interactions, and play an important role in inflammation, coagulation, and vascular function. [17] A recent study [24] found they may play important roles not only in homeostasis but also in the pathogenesis of a number of diseases such as vascular diseases, cancer, infectious diseases and diabetes mellitus.
HMG-CoA reductase inhibitors (statins) such as simvastatin have pleiotropic effects independent of lipid lowering. [25] [26] [27] Statin therapy has clinically beneficial effects on cardiovascular, cerebrovascular and acute and chronic kidney diseases via diverse effects. [26, 28, 29] The protective effects of statins on both human and animal sepsis have been recently reported. A retrospective study in humans reported that statin therapy reduced both overall and attributable mortality in patients with bacteremia. [30] A retrospective study [31] found that statin therapy is benefi cial for patients with sepsis. A controlled study [32] revealed that prior statin therapy was associated with a reduction of severe sepsis and intensive care unit admission. Simvastatin improved survival of animals in a murine CLP model. [33] Merx et al [34] reported that the average survival rate of septic mice using statin was 4 times higher than that of controls. Simvastatin reduces recruitment and activation of neutrophils, thereby protecting from LPS-induced ALI. Simvastatin improved sepsis-induced AKI by direct effects on the renal vasculature, reversal of tubular hypoxia, and a systemic anti-inflammatory effect. [35] Statins might improve microvascular dysfunction in sepsis. In rats, simvastatin attenuated the development of sinusoidal endothelial dysfunction induced by LPS administration through restoring a physiologic phosphorylated endothelial nitric oxide synthase (PeNOS)/endothelial nitric oxide synthase (eNOS) ratio, suggesting that statins might have potential for liver protection during endotoxemia. [36] Pretreatment with simvastatin protected against alphatoxin-induced sepsis associated with reduced p53, TNFalpha, apoptosis, and necrosis. [37] Apoptosis is termed programmed cell death because it is a series or program of coordinated processes. [38] Apoptosis is induced through two major signaling cascades, which are termed the extrinsic and intrinsic pathways. In the extrinsic pathway, external proteins bind to cell-surface receptors that subsequently induce apoptosis. Eventually caspase-3 becomes activated; caspase-3 has been termed the master executioner. The intrinsic pathway is the mitochondrial mediated pathway of apoptosis. A balance exists between (a) antiapoptotic proteins such as BCL-2, BCL-XL, and several others; and (b) proapoptotic proteins such as Bim, Bax, and PUMA. The proapoptotic proteins induce mitochondria to release cytochrome c, which activates caspase-9 through a series of events. As in the extrinsic pathway, caspase-3 becomes activated as a terminal event.
[1]
The Bc1-2 family plays an important role in transduction apoptotic signal within the cell. Bcl-2 and Bax genes in the Bcl-2 family have a close relationship with the apoptosis, the former is anti-apoptotic genes, the latter is pro-apoptotic genes. The balance of them affect the apoptosis. [39] A study has showed that Bcl-2 inhibits cell apoptosis through various ways: Bax-mediated apoptosis, inhibition of release of calcium ion in endoplasmic reticulum, antioxidant, etc. [40] Our study showed that apoptotic HUVECs increased signifi cantly, Bcl-2 mRNA upregulated, and Bax mRNA of HUVECs downregulated after incubation with septic serum of rats. The results suggested that sepsis may induce apoptosis after change of the balance of Bcl-2 mRNA and Bax mRNA.
However, after incubation with simvastatin, apoptotic HUVECs decreased significantly and the expression of Bcl-2 mRNA and Bax mRNA was changed inversely. This change shows that simvastatin inhibits sepsisinduced endothelial cell apoptosis by upregulating the Bcl-2 gene and downregulating the Bax gene.
At present, the effect of statins on apoptosis is still controversial. A study [41] showed that simvastatin decreased the TNF-alpha-induced apoptosis in endothelial progenitor cells by promoting the expression of silent information regulator type-1. Another study [42] showed that simvastatin triggers cell death in LPSactivated RAW 264.7 mouse macrophage cells through both caspase-dependent and independent apoptotic pathways. The nuclear orphan receptor NR4A1 expression and mitochondrial translocation of Bax are related to simvastatin-induced apoptosis in LPSactivated RAW 264.7 macrophages. These studies suggested that statins play different roles in apoptosis or anti-apoptosis through different pathways because of different pathophysiological causes. However, the specifi c mechanisms still need further study. If the role of statins in reducing mortality and improving the prognosis of sepsis patients is proved, it will be a signifi cant basis for the clinical use of statins for sepsis.
In conclusion, our study suggests that simvastatin can inhibit apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. It may be one of the mechanisms for simvastatin to treat sepsis.
